Bio Green Med Solution (BGMS) Receivables (2011 - 2026)

Bio Green Med Solution (BGMS) posted quarterly Receivables of $1.5 million for Q1 2026, up 17.26% quarter-over-quarter from $1.3 million in Q4 2025.

Analysis

Bio Green Med Solution (BGMS) Receivables (2011 - 2026) Analysis & Trends

Bio Green Med Solution (BGMS) has reported Receivables for 10 consecutive years, with $1.5 million the latest figure, recorded in Q1 2026.

In Q1 2026, Receivables changed N/A year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $1.5 million (changed N/A YoY), while the FY2025 annual figure was $1.7 million, changed N/A from the prior year.
Receivables improved to $1.5 million in Q1 2026 per BGMS's latest filing, from $1.3 million in the prior quarter.
Across five years, Receivables topped out at $1.5 million in Q1 2026 and bottomed at $725000.0 in Q3 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Vertex Pharmaceuticals	141.37 Bn	133.51 Bn	2.84 Bn	2.13 Bn
2	Regeneron Pharmaceuticals	86.46 Bn	78.46 Bn	3.93 Bn	6.57 Bn
3	Argenx Se	64.88 Bn	59.70 Bn	1.37 Bn	1.93 Bn
4	Moderna	57.86 Bn	52.72 Bn	52.00 Mn	160.00 Mn
5	Revolution Medicines	44.54 Bn	44.54 Bn	-	-
6	BeOne Medicines	40.43 Bn	35.33 Bn	1.53 Bn	1.06 Bn
7	Alnylam Pharmaceuticals	35.12 Bn	31.81 Bn	992.69 Mn	912.74 Mn
8	Royalty Pharma	28.35 Bn	27.51 Bn	-	-
9	Insmed	27.23 Bn	26.07 Bn	358.27 Mn	215.33 Mn
10	Bio Green Med Solution	5.21 Mn	1.42 Mn	79,000.00	1.61 Mn

Historic Data

Download Data